Envista Holdings Corporation (NYSE:NVST - Get Free Report) crossed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $25.75 and traded as high as $26.44. Envista shares last traded at $25.9830, with a volume of 3,424,316 shares changing hands.
Analysts Set New Price Targets
NVST has been the topic of a number of research reports. Leerink Partners dropped their price objective on Envista from $35.00 to $32.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 14th. Mizuho set a $29.00 price objective on Envista in a report on Thursday, August 6th. JPMorgan Chase & Co. raised Envista from a "neutral" rating to an "overweight" rating and raised their target price for the company from $29.00 to $32.00 in a research note on Thursday, September 3rd. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Envista in a report on Tuesday, November 3rd. Finally, Zacks Research cut shares of Envista from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 5th. Six equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Envista currently has an average rating of "Hold" and an average price target of $29.00.
View Our Latest Report on NVST
Envista Stock Performance
The firm has a market capitalization of $4.17 billion, a PE ratio of 6.71, a P/E/G ratio of 1.38 and a beta of 0.94. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.43 and a quick ratio of 2.07. The firm has a fifty day moving average price of $24.36 and a 200 day moving average price of $25.75.
Envista (NYSE:NVST - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.40 earnings per share for the quarter, topping analysts' consensus estimates of $0.36 by $0.04. The firm had revenue of $691.50 million for the quarter, compared to analysts' expectations of $688.74 million. Envista had a return on equity of 8.26% and a net margin of 22.01%. Envista's revenue was up 3.2% on a year-over-year basis. During the same quarter last year, the business posted $0.32 EPS. Research analysts anticipate that Envista Holdings Corporation will post 1.56 earnings per share for the current fiscal year.
Insider Activity at Envista
In other news, SVP Mischa Reis sold 8,000 shares of Envista stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $27.50, for a total value of $220,000.00. Following the transaction, the senior vice president directly owned 27,321 shares of the company's stock, valued at $751,327.50. This trade represents a 22.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.99% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Envista
Several hedge funds have recently made changes to their positions in the company. Corient Private Wealth LP raised its holdings in shares of Envista by 35.8% during the second quarter. Corient Private Wealth LP now owns 703,864 shares of the company's stock worth $18,547,000 after acquiring an additional 185,687 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Envista during the second quarter valued at $2,039,000. Legal & General Group Plc purchased a new position in Envista in the second quarter valued at about $5,987,000. WINTON GROUP Ltd grew its stake in Envista by 247.9% in the second quarter. WINTON GROUP Ltd now owns 192,055 shares of the company's stock valued at $5,061,000 after purchasing an additional 136,855 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in Envista in the second quarter valued at about $1,464,000.
About Envista
(
Get Free Report)
Envista Holdings Corporation is a dental products and technology company that develops and supplies tools and services for dental professionals. Its offerings span implant dentistry, orthodontics, digital imaging, restorative care and other clinical applications.
The company's products include dental implants and related treatment systems, orthodontic brackets and clear aligners, imaging equipment and software, and restorative and endodontic materials. Its brands include Nobel Biocare, Ormco, DEXIS, Kerr and KaVo.
Envista was formed in 2019 through the separation of Danaher Corporation's dental businesses.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Envista, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.
While Envista currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
